Imagine your body is like a house where a fire happened months ago; the fire is out, but some pipes are leaking and the wiring is frayed. This work identifies the specific 'leaks' in the heart, lungs, and kidneys using blood tests and digital clones of organs. It helps doctors spot who is at risk of permanent damage long after the initial sickness is gone.
Healthcare systems lack tools to identify and treat patients who develop heart, lung, and kidney diseases months after COVID-19. This leads to high socioeconomic costs and missed opportunities for early prevention.
The project is building knowledge-based biomarkers, a virtual twin model for clinical decision support, and standardized clinical guidelines for post-acute COVID care.
If you are a lab provider dealing with a lack of specific tests for long-term recovery — this project developed knowledge-based biomarkers that allow for better targeted monitoring panels for heart, lung, and kidney health.
If you are a software developer dealing with the need for precise patient forecasting — this project developed a virtual twin model that simulates disease mechanisms to forecast individual risk for clinicians.
If you are a clinic manager dealing with inconsistent patient follow-up protocols — this project developed clinical guidelines and decision support tools to help doctors act on risk in a consistent way across Europe.
Based on available project data, no specific pricing or cost structure for the model has been disclosed.
The project uses data from cohorts of more than 6 million Europeans and biobanks from over 6,000 people, suggesting a strong foundation for large-scale application.
Based on available project data, specific licensing terms are not mentioned, though the project works with standards bodies to ensure interoperability.
The project liaises with standards bodies to ensure that the emerging tools are usable, explainable, and interoperable in everyday care.
The project period runs from 2024-01-01 to 2027-12-31, indicating a timeline for development and validation through 2027.
The consortium is heavily weighted toward research and academia, with 3 universities and 2 research institutes. However, it includes a strategic mix of 10 partners across 8 countries, including 2 SMEs and 1 industrial partner. The inclusion of an end-user organization representing over 120,000 physicians provides a direct bridge to market adoption and clinical validation.
Contact KOBENHAVNS UNIVERSITET regarding the POINT project coordination.
Contact us to track the development of the virtual twin risk models for your diagnostic pipeline.
